Aktie A3D38R AYTU BIOPHARMA, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Aytu BioPharma, Inc.

Aktien

A3D38R

US0547548588

AYTU

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:01 03.05.2024 		% 5 Tage % 1. Jan.
3,01 USD 0,00 % Intraday Chart für Aytu BioPharma, Inc. +3,64 % +5,99 %
14.02. Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
14.02. Aytu BioPharma, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
AYTU BIOPHARMA, INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain to the Board of Directors
Aytu BioPharma : Presentation
Aytu BioPharma : Submission of Matters to a Vote of Security Holders - Form 8-K
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D38R Aktie
  4. Nachrichten Aytu BioPharma, Inc.
  5. Andere Sprachen